Zenggeng Wang1,2, Qinghua Wu3, Xiangbi Nie4, Jinghua Guo4, Chunli Yang4. 1. Medical College of Nanchang University, Nanchang, 330006, Jiangxi, China. zenggengwangw@163.com. 2. ICU, Jiangxi Provincial People's Hospital, No. 92 Patriotic Way, Nanchang, 330006, Jiangxi, China. zenggengwangw@163.com. 3. Department of Cardiology, The Second Affiliated Hospital to Nanchang University, Nanchang, 30006, Jiangxi, China. 4. ICU, Jiangxi Provincial People's Hospital, No. 92 Patriotic Way, Nanchang, 330006, Jiangxi, China.
Abstract
BACKGROUND AND OBJECTIVE: As a β-adrenoceptor antagonist (β-blocker), esmolol can reduce cardiac output and the phosphodiesteraseIII inhibitor milrinone has been shown to improve heart contractility in patients with septic shock. This study was performed to assess the effects of esmolol combined with milrinone in patients with severe sepsis. METHODS: This prospective randomized study was conducted in patients with severe sepsis in the intensive care unit of the Jiangxi Provincial People's Hospital (Nanchang, Jiangsu, China) between June 2013 and June 2014. Patients were randomly divided into control (C), milrinone (M), and milrinone-esmolol (ME) groups. The primary outcome was the rate of controlling the heart rate (HR) to achieve target levels. Secondary outcomes included the 28-day survival rate and changes in hemodynamic variables, organ function variables, myocardial injury markers, and the serum levels of proinflammatory factors. RESULT: A total of 90 patients with severe sepsis were included in this study (30 per group). The HR in the ME group was lower than in the M and C groups after 12 h. The rate of successful HR control during the first 96 h was significantly higher in the ME group (60.0 vs. 33.3 % in the M group, vs. 26.7 % in the C group). Also, patients in the ME group had higher 28-day overall survival compared with the M (Log rank statistic = 5.452; P = 0.020) and C groups (Log rank statistic = 10.206; P = 0.001). Additionally, several variables showed significant improvement in the ME group 96 h after treatment compared with the M and C groups (P < 0.05). CONCLUSION: Combination therapy with milrinone and esmolol could improve cardiac function and the 28-day survival rate in patients with severe sepsis.
RCT Entities:
BACKGROUND AND OBJECTIVE: As a β-adrenoceptor antagonist (β-blocker), esmolol can reduce cardiac output and the phosphodiesterase III inhibitor milrinone has been shown to improve heart contractility in patients with septic shock. This study was performed to assess the effects of esmolol combined with milrinone in patients with severe sepsis. METHODS: This prospective randomized study was conducted in patients with severe sepsis in the intensive care unit of the Jiangxi Provincial People's Hospital (Nanchang, Jiangsu, China) between June 2013 and June 2014. Patients were randomly divided into control (C), milrinone (M), and milrinone-esmolol (ME) groups. The primary outcome was the rate of controlling the heart rate (HR) to achieve target levels. Secondary outcomes included the 28-day survival rate and changes in hemodynamic variables, organ function variables, myocardial injury markers, and the serum levels of proinflammatory factors. RESULT: A total of 90 patients with severe sepsis were included in this study (30 per group). The HR in the ME group was lower than in the M and C groups after 12 h. The rate of successful HR control during the first 96 h was significantly higher in the ME group (60.0 vs. 33.3 % in the M group, vs. 26.7 % in the C group). Also, patients in the ME group had higher 28-day overall survival compared with the M (Log rank statistic = 5.452; P = 0.020) and C groups (Log rank statistic = 10.206; P = 0.001). Additionally, several variables showed significant improvement in the ME group 96 h after treatment compared with the M and C groups (P < 0.05). CONCLUSION: Combination therapy with milrinone and esmolol could improve cardiac function and the 28-day survival rate in patients with severe sepsis.
Authors: Kada Klouche; Stephane Pommet; Laurent Amigues; Anne Sophie Bargnoux; Anne Marie Dupuy; Sonia Machado; Marianne Serveaux-Delous; Marion Morena; Olivier Jonquet; Jean Paul Cristol Journal: J Intensive Care Med Date: 2013-01-01 Impact factor: 3.510
Authors: Kathleen E Singer; Courtney E Collins; Julie M Flahive; Allison S Wyman; M Didem Ayturk; Heena P Santry Journal: Am J Surg Date: 2017-06-24 Impact factor: 2.565
Authors: Samuel M Brown; Sarah J Beesley; Michael J Lanspa; Colin K Grissom; Emily L Wilson; Samir M Parikh; Todd Sarge; Daniel Talmor; Valerie Banner-Goodspeed; Victor Novack; B Taylor Thompson; Sajid Shahul Journal: Pilot Feasibility Stud Date: 2018-08-03
Authors: Geert Koster; Hanneke J Bekema; Jørn Wetterslev; Christian Gluud; Frederik Keus; Iwan C C van der Horst Journal: Intensive Care Med Date: 2016-07-22 Impact factor: 17.440
Authors: Martin Unger; Andrea Morelli; Mervyn Singer; Peter Radermacher; Sebastian Rehberg; Helmut Trimmel; Michael Joannidis; Gottfried Heinz; Vladimír Cerny; Pavel Dostál; Christian Siebers; Fabio Guarracino; Francesca Pratesi; Gianni Biancofiore; Massimo Girardis; Pavla Kadlecova; Olivier Bouvet; Michael Zörer; Barbara Grohmann-Izay; Kurt Krejcy; Christoph Klade; Günther Krumpl Journal: Trials Date: 2018-11-19 Impact factor: 2.279